129 related articles for article (PubMed ID: 15461062)
1. Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease.
Schrör K; Hohlfeld T
Vasa; 2004 Aug; 33(3):119-24. PubMed ID: 15461062
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
3. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
[TBL] [Abstract][Full Text] [Related]
4. [Microcirculation in peripheral arterial occlusive diseases will improve. Prostaglandin can prevent surgery].
MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974333
[No Abstract] [Full Text] [Related]
5. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E1-therapy reduces circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1) in peripheral vascular disease.
Palumbo B; Oguogho A; Fitscha P; Sinzinger H
Vasa; 2000 Aug; 29(3):179-85. PubMed ID: 11037715
[TBL] [Abstract][Full Text] [Related]
7. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor.
Makino H; Aoki M; Hashiya N; Yamasaki K; Hiraoka K; Shimizu H; Azuma J; Kurinami H; Ogihara T; Morishita R
Hypertens Res; 2004 Feb; 27(2):85-91. PubMed ID: 15005271
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacologic concepts for clinical use of prostaglandin E1].
Schrör K
Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of peripheral arterial diseases].
Mikita J
Orv Hetil; 2005 May; 146(22):1209-11. PubMed ID: 15997667
[No Abstract] [Full Text] [Related]
10. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
[TBL] [Abstract][Full Text] [Related]
11. Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1.
Weiss T; Fischer D; Hausmann D; Weiss C
Prostaglandins Leukot Essent Fatty Acids; 2002 Nov; 67(5):277-81. PubMed ID: 12445486
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV.
Creutzig A; Lehmacher W; Elze M
Vasa; 2004 Aug; 33(3):137-44. PubMed ID: 15461065
[TBL] [Abstract][Full Text] [Related]
13. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
Thum J; Caspary L; Creutzig A; Alexander K
Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
[TBL] [Abstract][Full Text] [Related]
14. The effect of intraportal prostaglandin E1 on adhesion molecule expression, inflammatory modulator function, and histology in canine hepatic ischemia/reperfusion injury.
Hafez T; Moussa M; Nesim I; Baligh N; Davidson B; Abdul-Hadi A
J Surg Res; 2007 Mar; 138(1):88-99. PubMed ID: 17174338
[TBL] [Abstract][Full Text] [Related]
15. A comparison of the effect of Lipo PGE1 and other related compounds on experimental peripheral arterial occlusive disease in rats.
Goto J; Araki H; Otomo S; Aihara H
Drugs Exp Clin Res; 1986; 12(11):917-21. PubMed ID: 3816509
[TBL] [Abstract][Full Text] [Related]
16. [Fibrinolytic activity, thrombocyte function and pharmacokinetics during intra-arterial or intravenous prostaglandin E1 infusion in patients with chronic arterial occlusive disease].
Fitscha P; Simmet T; Peskar BA; Reuter H; Sinzinger H; Rogatti W; Tilsner V
Wien Klin Wochenschr; 1988 Jul; 100(14):477-81. PubMed ID: 3062905
[TBL] [Abstract][Full Text] [Related]
17. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease.
Gianetti J; De Caterina M; De Cristofaro T; Ungaro B; Guercio RD; De Caterina R
Am Heart J; 2001 Oct; 142(4):733-9. PubMed ID: 11579367
[TBL] [Abstract][Full Text] [Related]
18. Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of peripheral artery occlusive disease.
Bitto A; Polito F; Altavilla D; Minutoli L; Migliorato A; Squadrito F
J Vasc Surg; 2008 Nov; 48(5):1292-300. PubMed ID: 18971038
[TBL] [Abstract][Full Text] [Related]
19. Effect of intravenous iloprost and alprostadil (PGE1) on peripheral resistance during femoro-distal reconstructions.
Krueger U; Scholz H; Heise M; Adeberg P; Petzold M; Zanow J; Karrenberg R
Int Angiol; 2000 Dec; 19(4):358-65. PubMed ID: 11305737
[TBL] [Abstract][Full Text] [Related]
20. [The pharmacology and clinical aspects of the prostanoids].
Ambrosioni E; Degli Esposti D
Ann Ital Med Int; 1993 Oct; 8 Suppl():59S-65S. PubMed ID: 8117524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
